Business & Industry
Seamless Therapeutics and Eli Lilly Hearing Loss Collaboration
Seamless Therapeutics has entered a global research collaboration and licensing agreement with Eli Lilly and Company under the Seamless Therapeutics Eli Lilly hearing loss collaboration, focused on developing programmable recombinase-based genetic medicines for hearing loss.
The collaboration will unite Seamless...
Business & Industry
AstraZeneca CSPC Weight-Loss Deal Reaches $18.5 Billion
AstraZeneca has agreed to license experimental obesity and metabolic disease drugs from China’s CSPC Pharmaceutical Group under the AstraZeneca CSPC weight-loss deal, with total potential payments reaching $18.5 billion.
The agreement includes $1.2 billion paid upfront, with up to $17.3...
News
Therapeutic Frontiers in Malignant Mesothelioma Management
Malignant mesothelioma is one of oncology’s most challenging diagnoses. This aggressive cancer, primarily linked to asbestos exposure, has long represented a high-unmet-need indication where treatment options remained frustratingly limited. For decades, platinum-based chemotherapy served as the backbone of care,...
News
CRO Clinical Trials: Structure and Purpose in Modern Research
Clinical trials require carefully organized processes to ensure that medical research is conducted ethically, consistently, and in line with regulatory expectations. As studies grow in scale and complexity, many sponsors rely on external operational support to manage these requirements....
Drug Research
AstraZeneca-Modella AI Acquisition to Speed Oncology R&D
AstraZeneca has agreed to acquire Boston-based Modella AI as drugmakers continue to increase their use of artificial intelligence to accelerate research and development. Financial terms of the deal were not disclosed.
Modella AI said its foundation models and AI agents...
Business & Industry
Novartis, SciNeuro Brain Shuttle Deal Expands Neuroscience
Novartis has entered into a licensing agreement with SciNeuro Pharmaceuticals focused on improving drug delivery to the brain. The Novartis and SciNeuro brain shuttle deal is valued at up to $1.7 billion and centers on an antibody-based program designed...
News
Bayer-Attralus Diagnostic Tracers Deal Expands Imaging Reach
In order to broaden its portfolio in imaging and cardiovascular medicine, Bayer has agreed to purchase two experimental diagnostic imaging agents from Attralus. The Bayer-Attralus diagnostic tracers deal's financial details were not made public.
Two imaging tracers, AT-01 and AT-05,...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read